- Member Center
- Professional Groups
LES hosts monthly webinars as part of its ongoing Webinar Wednesday series, as well as hot topic webinars that are periodically scheduled to cover breaking developments such as patent reform, important case updates, and other major industry news. Webinar Wednesday is held on the second Wednesday of each month at 1:00 p.m. Eastern Time (EST), and are also available anytime on-demand. Join intellectual property (IP) and licensing experts as they share their knowledge and experience regarding today’s most relevant licensing trends and challenges from transnational issues to ethics to valuation.
If you would like to propose or present a topic, please complete this form.
*FREE for LES members: All webinars, a $1,500 value, are FREE for LES members. Register today!
Who Should Attend
The webinars are designed for all IP and licensing professionals at any level of experience, including corporate IP and licensing professionals, technology transfer professionals, non-IP attorneys, and business development professionals.
Why You Should Attend
LES webinars are a convenient and affordable way to stay up-to-date with current trends and challenges, gain core knowledge on IP and licensing topics, and supplement your learning in new areas. With our live webinars and growing library of on-demand webinars, you can log-in and learn from leading industry experts anywhere, anytime.
Each webinar is 60 or 90 minutes and addresses a unique topic presented by different industry experts. Sample topics include patent reform, trademark licensing, royalty auditing, patent sales agreements, antitrust issues, and patent licensing conflicts.
The Webinar Wednesday series is FREE to LES members! These webinars, delivered right to your desk, expand your knowledge and exposure to today’s hot topics.
LES USA & Canada & LES International Global Life Sciences
Date: Thursday, February 9, 2017
Time: 12:00 pm – 1:00 pm Eastern Time
Many sources of information on biopharmaceutical royalty rates and deal terms rely on either Freedom of Information (FOI) sources from public companies in the United States, which only represent "material" deals that are generally more than five years old, or rely on press releases or public announcements which are often positioned for maximum publicity or promotional impact (i.e., the hyperbole of "BIO Bucks").